Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers

PHASE2RecruitingINTERVENTIONAL
Enrollment

174

Participants

Timeline

Start Date

July 19, 2024

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2028

Conditions
Metastatic Colorectal Cancer
Interventions
PROCEDURE

Blood sample

Blood sample for plasma collection, Blood sample for ctDNA (circulating tumoral DNA) collection

OTHER

Quality of life questionnaires

EORTC QLQ-C30 questionnaire (Quality of life questionnaire Cancer 30) CR29 questionnaire (Colo-rectal cancer 29) EQ-5D5L questionnaire (EuroQol-5 Dimensions, 5 levels): repeated measures at baseline, M2, M4, M6, M8, M10, M12 and during the end of treatment visit and during the follow-up

PROCEDURE

Biopsy

Fresh tumor biopsy at baseline and week 8

DRUG

Regorafenib

"For the first cycle: Regorafenib will be administered according to the REDOS schedule: week 1: 80 mg regorafenib daily week 2: 120 mg regorafenib daily week 3: 160 mg regorafenib daily week 4 : OFF. For the following cycles: regorafenib will be administered at 160mg in the absence of significant toxicity during cycle 1 or at a 80/120mg daily dose according to toxicity observed with the last dose used in the first cycle."

COMBINATION_PRODUCT

Regorafenib + metronomic chemotherapy

"• Regorafenib will be administered 3 weeks out of 4 (1 cycle corresponding to 4 weeks) until progression or unacceptable toxicity.~For the first cycle: Regorafenib will be administered according to the REDOS schedule: week 1: 80 mg regorafenib daily week 2: 120 mg regorafenib daily week 3: 160 mg regorafenib daily week 4 : OFF. For the following cycles: regorafenib will be administered at 160mg in the absence of significant toxicity during cycle 1 or at a 80/120mg daily dose according to toxicity observed with the last dose used in the first cycle.~* Metronomic chemotherapy will be administrated as following:Cyclophosphamide: 50 mg per os, daily, for 6 months,Capecitabine: 625mg/m²/orally twice daily, for 6 months.~* Low-dose Aspirin: 75 mg orally, daily, until progression."

Trial Locations (10)

25000

RECRUITING

Centre Hospitalier Universitaire de Besançon, Besançon

Unknown

RECRUITING

CHU d'Auxerre, Auxerre

RECRUITING

CH de Colmar, Colmar

RECRUITING

Centre Georges-François Leclerc (CGFL), Dijon

RECRUITING

Hôpital Robert Schuman, Metz

RECRUITING

Hôpital Nord Franche-Comté, Montbéliard

RECRUITING

CHU de Montpellier, Montpellier

RECRUITING

CHU de Reims - Hôpital Robert Debré, Reims

NOT_YET_RECRUITING

Clinique Privée de Strasbourg, Strasbourg

RECRUITING

ICANS, Strasbourg

All Listed Sponsors
collaborator

Groupement Interrégional de Recherche Clinique et d'Innovation

OTHER

lead

Centre Hospitalier Universitaire de Besancon

OTHER